How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

779 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Cochrane team criticises the ECDC experts' draft advice on oseltamivir use

agents”, had been approved for treatment of dementia in the past [8-10]. Between 1998 and 1999, most of them were taken off the market. None of the medicines approved in or before 1998 still hold a clear indication for treatment of dementia today. Currently, only 4 medicines are indicated for treatment of dementia like in other countries; namely donepezil (brand name: Aricept etc.); cholinesterase inhibitors, galantamine Abstract ?Memantine (brand name: Memary), which was launched in 2011, increases

2016 Med Check - The Informed Prescriber

122. Parkinson's disease in adults.

of dementia with Lewy bodies. 6 At the time of publication (July 2017), rivastigmine capsules are the only treatment with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's for further information. 7

2017 National Guideline Clearinghouse (partial archive)

124. Speech therapy for treatment of adults with primary progressive aphasia

stimulation on language function in patients with acquired impairments of speech, and a limited number of studies have evaluated these techniques in patients with PPA. Patient Population: Speech therapy has been evaluated in adults with PPA. Clinical Alternatives: There are no approved medical disease-modifying treatments for patients with PPA. Pharmacological interventions are of limited value, and include galantamine, memantine, amphetamine, bromocriptine, and modafinil. Other indirect interventions

2016 Health Technology Assessment (HTA) Database.

125. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

the four year study period. The participants in each group had similar characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option (...) characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option to treat cognitive symptoms of mild to moderate Alzheimer’s disease, provided

2018 NIHR Dissemination Centre

126. Clinical practice guidelines and principles of care for people with dementia

AND MEMANTINE 69 EBR Low Any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine) are recommended as options for managing the symptoms of mild to moderately severe Alzheimer's disease. Any one of the three acetylcholinesterase inhibitors could be considered for managing the symptoms of severe Alzheimer’s disease. 2 Prior to initiation of treatment medical practitioners should consider performing an electrocardiogram (ECG), recording weight and undertaking a falls risk

2016 Clinical Practice Guidelines Portal

129. SNMMI Procedure Standard-EANM Practice Guideline for Amyloid PET Imaging of the Brain

prescribed for dementia patients, such as donepezil, galantamine, and memantine. No drug withdrawal is recommended at this time. 2. Information Pertinent to the Procedure: Several parameters should be taken into consideration in order to improve the quality of the study acquisition and reporting: a) Correlation (preferably using digital image co-registration) with recent or concurrent morphologic imaging studies (e.g. CT, MRI) is recommended to evaluate the amount and location of brain atrophy as well

2016 Society of Nuclear Medicine and Molecular Imaging

130. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

the four year study period. The participants in each group had similar characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option (...) characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option to treat cognitive symptoms of mild to moderate Alzheimer’s disease, provided

2018 NIHR Dissemination Centre

132. Pharmacological interventions for cognitive decline in people with Down syndrome. (PubMed)

Pharmacological interventions for cognitive decline in people with Down syndrome. People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population. Alzheimer's disease and cognitive decline in people with Down syndrome can place a significant burden on both the person with Down syndrome and their family and carers. Various pharmacological interventions, including donepezil, galantamine, memantine and rivastigmine, appear to have some effect

Full Text available with Trip Pro

2015 Cochrane

133. Recommendations on screening for cognitive impairment in older adults

important change. The MMSE and the MoCA tools are commonly used by Canadian clinicians in clinical practice. 14 Treatments include medications such as cho- linesterase inhibitors (i.e., donepezil, rivastigmine and galantamine), dietary supplements and vita- mins, and nonpharmacologic interventions such as exercise, and cognitive training and rehabili- tation. 10 Provincial payment for the medications used in primary care practice is often linked to cognitive assessment scores measured by the screening (...) interventions approved for use in Canada (e.g., cholinesterase inhibitors, such as donepezil, rivastigmine and galantamine), dietary supplements or vitamins and nonpharmacologic interventions (e.g., exer- cise, cognitive training and rehabilitation). The task force workgroup decided to treat the key question regarding the accuracy of screening tools (key question 6 in Appendix 2) as a contex- tual question. This was because there were no trials of screening programs and there was evi- dence that treatment

2015 CPG Infobase

134. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. (PubMed)

patients at 119 sites; study 2: n = 858 at 158 sites; and study 3: n = 734 at 126 sites). The 24-week studies were conducted from October 2013 to January 2017; final follow-up on January 12, 2017.Idalopirdine (10, 30, or 60 mg/d) or placebo added to cholinesterase inhibitor treatment (donepezil in studies 1 and 2; donepezil, rivastigmine, or galantamine in study 3).Primary end point in all 3 studies: change in cognition total score (range, 0-70; a lower score indicates less impairment) from baseline

Full Text available with Trip Pro

2018 JAMA

135. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0

orbreasttissue.However,forcautioninthisrareinstanceandbecause of the potential for radiotracer excretion in human milk and potential radiation exposure to infants, either avoid performing amyloid PET imaging on a breastfeeding mother or have the mother interrupt breastfeeding for 24 h after administration of the 18 F radiotracer. There is no known evidence to suggest that there are drug interactions between amyloid radiotracers and common drugs pre- scribed for dementia patients, such as donepezil, galantamine

2016 European Association of Nuclear Medicine

136. Drugs to avoid in 2015

of their disproportionate adverse effects and many interactions with other drugs. None of the available drugs has been shown to slow progression toward dependency, yet all carry a risk of life-threatening adverse effects and severe drug inter - actions (Prescrire Int n° 128 and Rev Prescrire n° 363, 364). It is better to focus on reorganising the patient’s daily life, keeping him or her active, and providing support and help for caring relatives. – Donepezil, galantamine and rivastigmine, three cholinesterase

2015 Prescrire

137. Inhibition of Human P-glycoprotein Transport and Substrate Binding Using a Galantamine Dimer (PubMed)

Inhibition of Human P-glycoprotein Transport and Substrate Binding Using a Galantamine Dimer The human multidrug resistance transporter P-glycoprotein (P-gp) prevents the entry of compounds into the brain by an active efflux mechanism at the blood-brain barrier (BBB). Treatment of neurodegenerative diseases, therefore, has become a challenge and the development of new reversible inhibitors of P-gp is pertinent to overcome this problem. We report the design and synthesis of a crosslinked agent (...) based on the Alzheimer's disease treatment galantamine (Gal-2) that inhibits P-gp-mediated efflux from cultured cells. Gal-2 was found to inhibit the efflux of the fluorescent P-gp substrate rhodamine 123 in cancer cells that over-express P-gp with an IC(50) value of approximately 0.6 microM. In addition, Gal-2 was found to inhibit the efflux of therapeutic substrates of P-gp, such as doxorubicin, daunomycin and verapamil with IC(50) values ranging from 0.3 to 1.6 microM. Through competition

Full Text available with Trip Pro

2009 Biochemical and biophysical research communications

138. Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice (PubMed)

Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice Galantamine, a weak acetylcholine esterase (AChE) inhibitor and allosteric potentiator of nicotinic ACh receptors (nAChRs), improves apomorphine-induced deficits in prepulse inhibition (PPI), sensory information-processing deficits, via a nAChR-independent mechanism. The present study examined the role of muscarinic ACh receptors (mAChRs) in the effect of galantamine, and studied (...) the mechanism of galantamine-induced increases in prefrontal ACh levels in mice.Apomorphine (1 mg kg(-1)) was administered to male ddY mice (9-10 weeks old) to create a PPI deficit model. Extracellular ACh concentrations in the prefrontal cortex were measured by in vivo microdialysis.Galantamine- and donepezil-mediated improvements in apomorphine-induced PPI deficits were blocked by the preferential M(1) mAChR antagonist telenzepine. The mAChR agonist oxotremorine also improved apomorphine-induced PPI

Full Text available with Trip Pro

2009 British journal of pharmacology

139. Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia (CIDAR-3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01012167 Recruitment Status

2009 Clinical Trials

140. Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine

Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>